Digostics Announces University Trial of New At-home Type 1 Diabetes Test Underway
GTT@home is an OGTT developed by British diabetes home-testing company Digostics that uses finger-prick blood samples to measure how well the body processes glucose. The test, being studied at Yale School of Medicine in New Haven, Conn., has been shown to be as accurate as lab-based OGTTs when used in adults with glucose intolerance, type 2 diabetes, or in pregnant individuals to diagnosis gestational diabetes. The GTT@home test has successfully been implemented in several UK NHS Trusts to screen for gestational diabetes in pregnancy.
Dr. Jennifer Sherr, Professor of Pediatric Endocrinology and the Medical Director of Pediatric Diabetes at Yale School of Medicine and co-lead principal investigator of the trial, said: 'As the presence of diabetes autoantibodies foretells an eventual diagnosis of T1D, it is critical to conduct an OGTT to stage the disease, which helps predict the risk of progression over time. Yet, in the current paradigm this requires coming to a clinical center or laboratory and getting venous blood draws. Despite knowing there is an increased risk of diabetes many individuals struggle to undergo an OGTT for staging, or repeat the test to permit ongoing monitoring. An at-home OGTT would alleviate this barrier. The ability to have those at risk use a product that is simple, requires fingerpricks instead of venous draws, and can be done within a person's own home at a date and time that is convenient for them would be a fantastic step forward for both patients and providers.'
T1D can be diagnosed at any age, and it is the most common childhood autoimmune disease, affecting around one in 350 children. In T1D the body's immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in elevated blood glucose levels. It affects every aspect of health and well-being and results in lifelong insulin dependence and an increased risk of major health problems such as heart disease, blindness, and kidney failure. In 40% or more of children the diagnosis of T1D is not made until the child has become severely unwell and presents with metabolic decompensation, which is known as diabetic ketoacidosis (DKA), a life-threatening diabetes complication.
Dr. Raquel Lopez-Diez, Scientist at Breakthrough T1D commented, 'Breakthrough T1D is excited to fund this important work with Yale University School of Medicine to explore an at-home alternative to OGTT for glycemic monitoring in the early stages of type 1 diabetes. Traditional in-clinic OGTTs are time-consuming, can be challenging to navigate for younger individuals, and require significant clinic resources. As new therapies emerge that can delay and, hopefully, one day prevent the progression of type 1 diabetes, it is critical to have the tools to accurately and reliably monitor and diagnose the early stages of the disease. A validated at-home testing approach would represent a major breakthrough. We look forward to seeing the results of this important study.'
T1D develops in stages over time, and early stages can be detected through a simple blood test. In stage 1 the body develops islet autoantibodies but the blood glucose levels are still normal. In stage 2, islet autoantibodies are present and individuals experience abnormal blood glucose or dysglycemia, and by stage 3 an individual has the clinical diagnosis of T1D and symptoms may begin to appear due to significant loss of insulin-producing cells.
The OGTT is the gold-standard test recommended for defining the stage of T1D a person is experiencing, and it is the most sensitive test for monitoring T1D stages 1 and 2. Hospital-based OGTTs are often not well tolerated because they require placement of an intravenous line inserted into the vein or multiple blood draws, as several blood samples taken over 2-hours in a healthcare setting.
Study lead Dr. Alfonso Galderisi, Associate Professor of Pediatrics at Yale School of Medicine, confirmed that the study will recruit 60 patients aged eight and over. 'To understand the ease of conducting the test, participants will complete an unsupervised GTT@home test. Five to seven days later, participants will come to our research unit and we will conduct the standard of care OGTT alongside a supervised GTT@home, with the results of the two tests compared to assess accuracy. We will also be interviewing participants to assess their perception of the two methods used to conduct OGTTs.'
Glucose tolerance tests are performed in the morning after an overnight fast. The GTT@home test kit contains the test device, finger prickers for blood sample collection, a preformulated glucose drink, and detailed instructions. The process begins with an initial finger prick blood sample, followed by the consumption of the glucose drink. Two hours later, a second blood sample is taken. With standard clinic-based OGTTs, individuals need to travel to a clinic early in the morning and then undergo the two blood draws two hours apart and have an IV inserted.
The GTT@home device analyses blood samples shortly after completion of the test and shares results in a timely manner directly with the study teams or clinician. Expedited analysis of samples eliminates the risk of sample degradation that can affect hospital-based OGTTs when samples are not sent to the lab immediately, improving diagnostic reliability.
"The support from Breakthrough T1D and the team at Yale School of Medicine underscores once again the huge potential for our at-home OGTT for use in T1D," said James Jackson, CEO and Founder of Digostics. "We are working closely with the Yale study team to support this trial.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the Phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the Phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified. 'While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab.' Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting. About the ALIENTO and ARNASA studies Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signaling of IL-33. The astegolimab COPD pivotal program consists of two registrational studies, the Phase IIb ALIENTO (NCT05037929) and Phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multi-center studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualized rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations - inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit
Business Wire
9 hours ago
- Business Wire
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognize Share Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at
USA Today
2 days ago
- USA Today
What are the symptoms of celiac disease?
If you've ever felt bloated or fatigued after eating a slice of pizza or a toasted bagel, it could be more than indigestion alone. Celiac disease is an underdiagnosed and serious chronic condition that affects some 2 million people in the U.S. each year and millions more across the globe. For the individuals dealing with it, avoiding gluten is anything but a "fad" diet; it's a medical necessity. "Celiac disease is an autoimmune disorder in which eating the gluten that's found in wheat, barley and rye leads to the body's immune cells attacking the lining of the small intestine," explains Dr. Marie Robert, a surgical pathologist at Yale School of Medicine New Haven Hospital. This can cause a wide variety of unwanted symptoms in both adults and kids alike. "While in the past celiac disease was thought to mainly affect children, it is now clear that it can occur at any age," says Dr. Alessio Fasano, a professor of nutrition at Harvard T.H. Chan School of Public Health and the pediatrics director of the Center for Celiac Research and Treatment at Massachusetts General Hospital. Here's what the most common symptoms of celiac disease are, what causes it and how it is usually treated. What are the symptoms of celiac disease? Celiac disease is a notoriously elusive condition because its symptoms vary in severity and can look different from one person to the next. Digestive issues are the most common symptom, and include "bloating, stomach pain and diarrhea," says Dr. Runa Watkins, a division chief in the pediatric gastroenterology and nutrition division at the University of Maryland School of Medicine. But because "there is no tissue or organ that's spared by the inflammatory process started by celiac disease," Fasano explains, many people with the disease also have non-gastrointestinal symptoms. These symptoms may include fatigue, anemia, joint pain, skin rashes and neurological symptoms like depression, brain fog, mood swings or headaches. "Reproductive issues such as infertility are also not uncommon,' adds Robert. Kids with celiac disease may also experience growth delays and short stature. 'Growth failure in children is another common sign of the disease,' says Dr. Peter Green, a physician and professor at the Celiac Disease Center at Columbia University. And when celiac disease goes untreated or undiagnosed – as it commonly does – the condition can lead to more serious complications such as other autoimmune diseases and osteoporosis. There's also a potential for increased risk of cancerous tumors and fractures due to chronic nutrient deficiencies. Due to all such factors, 'those with celiac disease face a higher mortality rate than the general population," says Green. Did you know? Acid reflux impacts about 20% of American adults. What causes it? What causes celiac disease? While the exact cause of celiac disease is not always known, Watkins says it's usually driven by a mix of genetic and environmental factors. When it comes to genetic associations, research shows that the strongest link is someone having what are known as the HLA-DQ2 or HLA-DQ8 gene variants. 'Because of these genes, up to 10% to 15% of first-degree relatives of celiac disease patients are affected,' says Fasano. As for environmental factors, eating gluten is what most commonly triggers symptoms in people with celiac disease, but "changes in the gut ecosystem – often caused by an infection (especially during childhood), surgery or stress – can also start the march from genetic predisposition to clinical outcome," explains Fasano. Need to avoid gluten? Here's what foods have gluten and more on hidden sources of gluten How is celiac disease treated? As of now, the only treatment for celiac disease is a strict gluten-free diet. 'Even small amounts of gluten, like crumbs from a toaster, can cause damage and symptoms,' says Watkins. But once gluten is eliminated completely, many patients feel better within weeks – though recovery may take longer for some people. Most of these patients work with a medical provider or dietitian to identify and eliminate food sources that contain gluten and to get recommendations on how to make up for nutritional deficiencies. This can be easier said than done though as, in addition to being a protein naturally found in many grains, gluten is "often added to processed foods as a filler," says Fasano. "Sauces, candies and even some meats may contain it." And for a small number of patients, even committing wholly to a gluten-free diet won't be enough to stave off symptoms. This is due to a rare condition called refractory celiac disease, which requires specialized treatment. For these and all patients with celiac disease, "there are numerous clinical trials attempting to find medicines that will prevent the associated inflammatory response," says Robert. "Hopefully, it's only a matter of time before there will be medicines that can make living with celiac disease easier."
